Evidence map›Paper›PMID 35214138›Full record

ArticlePharmaceutics2022

Physiologically Based Pharmacokinetic (PBPK) Model of Gold Nanoparticle-Based Drug Delivery System for Stavudine Biodistribution.

Hinojal Zazo, Clara I Colino, Carmen Gutiérrez-Millán, Andres A Cordero, Matthias Bartneck, José M Lanao

Abstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hinojal ZazoArea of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Avda Lcdo Méndez Nieto, 37007 Salamanca, Spain.ORCID 0000-0001-6753-4558
Clara I ColinoArea of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Avda Lcdo Méndez Nieto, 37007 Salamanca, Spain.ORCID 0000-0003-3642-4203
Carmen Gutiérrez-MillánArea of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Avda Lcdo Méndez Nieto, 37007 Salamanca, Spain.ORCID 0000-0003-0760-8636
Andres A CorderoArea of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Avda Lcdo Méndez Nieto, 37007 Salamanca, Spain.
Matthias BartneckDepartment of Medicine III, Medical Faculty, RWTH Aachen, Pauwelsstr. 30, 52074 Aachen, Germany.ORCID 0000-0003-1516-9610
José M LanaoArea of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Avda Lcdo Méndez Nieto, 37007 Salamanca, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Computational modelling has gained attention for evaluating nanoparticle-based drug delivery systems. Physiologically based pharmacokinetic (PBPK) modelling provides a mechanistic approach for evaluating drug biodistribution. The aim of this work is to develop a specific PBPK model to simulate stavudine biodistribution after the administration of a 40 nm gold nanoparticle-based drug delivery system in rats. The model parameters used have been obtained from literature, in vitro and in vivo studies, and computer optimization. Based on these, the PBPK model was built, and the compartments included were considered as permeability rate-limited tissues. In comparison with stavudine solution, a higher biodistribution of stavudine into HIV reservoirs and the modification of pharmacokinetic parameters such as the mean residence time (MRT) have been observed. These changes are particularly noteworthy in the liver, which presents a higher partition coefficient (from 0.27 to 0.55) and higher MRT (from 1.28 to 5.67 h). Simulated stavudine concentrations successfully describe these changes in the in vivo study results. The average fold error of predicted concentrations after the administration of stavudine-gold nanoparticles was within the 0.5-2-fold error in all of the tissues. Thus, this PBPK model approach may help with the pre-clinical extrapolation to other administration routes or the species of stavudine gold nanoparticles.

Indexed as

biodistributiongold nanoparticlesPBPK modelpharmacokineticsstavudine

Identifiers

PMID35214138
PMCPMC8875329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.